{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": [], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "15806739", "DateCompleted": {"Year": "2005", "Month": "04", "Day": "15"}, "DateRevised": {"Year": "2013", "Month": "11", "Day": "21"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "0097-6326", "JournalIssue": {"Volume": "70", "Issue": "63", "PubDate": {"Year": "2005", "Month": "Apr", "Day": "04"}}, "Title": "Federal register", "ISOAbbreviation": "Fed Regist"}, "ArticleTitle": "Use of ozone-depleting substances; removal of essential-use designations. Final rule.", "Pagination": {"StartPage": "17167", "EndPage": "17192", "MedlinePgn": "17167-92"}, "Abstract": {"AbstractText": ["The Food and Drug Administration (FDA) is amending its regulation on the use of ozone-depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for albuterol used in oral pressurized metered-dose inhalers (MDIs). Under the Clean Air Act, FDA, in consultation with the Environmental Protection Agency (EPA), is required to determine whether an FDA-regulated product that releases an ODS is an essential use of the ODS. Two albuterol MDIs that do not use an ODS have been marketed for more than 3 years. FDA has determined that the two non-ODS MDIs will be satisfactory alternatives to albuterol MDIs containing ODSs and is removing the essential-use designation for albuterol MDIs as of December 31, 2008. Albuterol MDIs containing an ODS cannot be marketed after this date."]}, "AuthorList": [{"AffiliationInfo": [], "Identifier": [], "CollectiveName": "Food and Drug Administration, HHS"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Fed Regist", "NlmUniqueID": "7808722", "ISSNLinking": "0097-6326"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Adrenergic beta-Agonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Air Pollutants"}, {"RegistryNumber": "0", "NameOfSubstance": "Chlorofluorocarbons"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "QF8SVZ843E", "NameOfSubstance": "Albuterol"}], "MeshHeadingList": [{"QualifierName": ["classification"], "DescriptorName": "Adrenergic beta-Agonists"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Air Pollutants"}, {"QualifierName": ["legislation & jurisprudence", "prevention & control"], "DescriptorName": "Air Pollution"}, {"QualifierName": ["classification", "therapeutic use"], "DescriptorName": "Albuterol"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Asthma"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Chlorofluorocarbons"}, {"QualifierName": [], "DescriptorName": "Costs and Cost Analysis"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["economics", "legislation & jurisprudence"], "DescriptorName": "Medicaid"}, {"QualifierName": ["economics", "legislation & jurisprudence"], "DescriptorName": "Medicare"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Metered Dose Inhalers"}, {"QualifierName": [], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "United States"}, {"QualifierName": [], "DescriptorName": "United States Environmental Protection Agency"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2005", "Month": "4", "Day": "6", "Hour": "9", "Minute": "0"}, {"Year": "2005", "Month": "4", "Day": "16", "Hour": "9", "Minute": "0"}, {"Year": "2005", "Month": "4", "Day": "6", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["15806739"]}}], "PubmedBookArticle": []}